Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2161584 | 0.75 | KDM4E (0.52) | MAPTDRD2DRD4DRD3KDM4E | |
| SCHEMBL2162623 | 0.74 | MEN1 (0.63) | GAADRD2DRD4DRD3KDM4E | |
| SCHEMBL2162347 | 0.73 | GAA (0.57) | GAAMAPTDRD2DRD4DRD3 | |
| SCHEMBL13496869 | 0.73 | KMT2A (0.56) | DRD2DRD4DRD3KDM4ETSHR | |
| SCHEMBL1714117 | 0.73 | SLC6A4 (0.58) | KDM4ETSHRTDP1TACR1HTR6 | |
| SCHEMBL2162820 | 0.72 | KMT2A (0.60) | GAAMAPTKDM4ETSHRLMNA | |
| SCHEMBL7607154 | 0.72 | DRD2 (0.54) | GAAMAPTDRD2DRD4DRD3 | |
| SCHEMBL2161582 | 0.72 | DRD2 (0.59) | GAAMAPTDRD2DRD4DRD3 | |
| SCHEMBL6192598 | 0.72 | DRD2 (0.54) | GAAMAPTDRD2DRD4DRD3 | |
| SCHEMBL2161683 | 0.72 | GAA (1.00) | GAAMAPTDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | claimed |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-26 | — | — | US | claimed |
| EP-2151777-A1 | Method for screening of 5HT7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-10 | — | — | EP | claimed |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-26 | — | — | US | disclosed |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-26 | — | — | US | disclosed |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-26 | — | — | US | disclosed |
| EP-2151777-A1 | Method for screening of 5HT7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-10 | — | — | EP | disclosed |
| EP-2151777-A1 | Method for screening of 5HT7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-10 | — | — | EP | disclosed |
| WO-2010012817-A2 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010012811-A2 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-04 | — | — | WO | disclosed |
| EP-2149373-A1 | 5HT7 receptor ligands and compositions comprising the same | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149373-A1 | 5HT7 receptor ligands and compositions comprising the same | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | HTR7, HTR1A, HTR6 | GAA 2744/4885MAPT 1023/4885DRD2 43/4885 |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | HTR7, HTR1A, HTR2C | GAA 2832/4885MAPT 1866/4885DRD2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.